Easi

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Acronym for Eczema Area and Severity Index. The EASI-Score is used to objectively measure the severity and spread of atopic eczema. It has been developed in strong analogy to the well-known PASI (Psoriasis Area and Severity Index). EASI assesses the disease activity by recording the severity of the disease, its spread or the affected area. Values between 0 and 72 can be calculated. The body is divided into four different body sections for assessment: head (K), trunk (R), arms (A) and legs (B). These are then weighted differently according to their percentage of the total surface area, adapted to age:
  • Patients > 8 years: K = 10%, A = 20%, R = 30%, B = 40%.
  • Patients < 8 years: K = 20%, A = 20%, R = 30%, B = 30%.
The extent of the disease is then determined for each individual body section. A numerical scale is used (0 = no involvement, 1 = < 10%, 2 = 10-30%, 3 = 30-50%, 4 = 50-70%, 5 = 70-90%, 6 = 90-100%). For the assessment of severity, skin lesions are rated on a scale of 0 to 3: 0 = none, 1 = low, 2 = medium, 3 = high. Erythema, infiltration, excoriation and lichenification are assessed in detail.

LiteratureThis section has been translated automatically.

  1. Barbier et al (2003) Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the Pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 150: 96-102

Authors

Last updated on: 29.10.2020